+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Radiodermatitis Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

  • PDF Icon

    Report

  • 206 Pages
  • February 2024
  • Region: Global
  • Infogence Global Research
  • ID: 5669345

The market is incorporating advanced wound care and regenerative therapies to alleviate skin damage caused by radiation treatments.

The Global Radiodermatitis Market is estimated to be USD 531.12 Mn in 2023 and is expected to reach USD 649.62 Mn by 2028 growing at a CAGR of 4.11%.

  • Radiodermatitis is a skin condition caused by ionizing radiation, which is utilized in cancer therapies such as radiotherapy. It causes irradiated skin to become inflamed, red, itchy, and sometimes blistered or ulcerated. Proper skin care and maintenance are critical for symptom relief and improving patients' quality of life throughout therapy.
  • The ageing population is a major market driver for radiodermatitis treatments. Cancer incidence climbs as people age, increasing demand for treatment. Because of their decreased skin resilience, the elderly may be more vulnerable to skin injury. As a result, increasing ageing population contributes to the overall growth of the radiodermatitis industry.
  • The increasing prevalence of cancer cases around the world has a direct impact on the radiodermatitis market. Radiotherapy is a prominent treatment technique for cancer patients, and the number of radiotherapy procedures is increasing as more people are diagnosed. The increased use of radiotherapy raises the risk of radiodermatitis, necessitating the development of appropriate medicines and therapies to manage this side effect.
  • The radiodermatitis market is being driven by the increasing use of radiotherapy as a primary cancer treatment. Technological advancements, greater treatment outcomes, and more knowledge of radiotherapy's benefits have led to its widespread use. As a result, the number of people suffering from radiodermatitis rises, creating a need for specialized products and procedures to control and alleviate the related skin disorders.
  • The increased desire for decreasing the side effects of radiation therapy creates a market opportunity for radiodermatitis. As radiotherapy becomes more widely used in cancer treatment, there is an increasing demand for effective treatments and therapies that help alleviate and manage radiodermatitis, thereby improving patients' quality of life during and after treatment.
  • However, the higher cost of managing radiodermatitis is a market restraint. Treatment costs, specialized skincare products, and supportive care can be costly, limiting access for some patients and providing financial obstacles for healthcare systems and people seeking effective radiodermatitis therapy.
  • The risk for chronic skin changes poses a market issue for radiodermatitis. Following radiation therapy, some patients may develop long-term or irreversible skin damage, demanding continuing monitoring and care. Addressing these persistent skin changes is difficult for healthcare practitioners and patients looking for effective remedies.

Market Segmentations

  • The Global Radiodermatitis Market is segmented based on Product, Distribution Channel, and Geography.
  • By Product, the Global Radiodermatitis Market is classified into Topical (Corticosteroid, Hydrophilic Creams, Topical Antibiotics, Others), Oral Drugs, and Dressings (Hydrogel & Hydrocolloid Dressings, No Sting Barrier Film, Honey-Impregnated Gauze, Silicone Coated).
  • Topical products, such as corticosteroids, hydrophilic creams, and topical antibiotics, hold a larger market share. They are chosen over oral medications or bandages due to their direct administration to the diseased area, which provides targeted treatment and convenience of usage.
  • By Distribution Channel, the Global Radiodermatitis Market is classified into Hospital Pharmacies, Retail Pharmacy, and Online Pharmacy.
  • Hospital Pharmacy holds a significant market share. As radiation treatments usually take place in hospitals, healthcare experts can directly prescribe and dispense specialized items, resulting in increased sales through hospital pharmacies.
  • By Geography, the Global Radiodermatitis Market is classified into the Americas, Europe, Middle-East & Africa, and Asia-Pacific.
  • The Americas hold a larger market share. This is due to the region's advanced healthcare infrastructure, higher cancer prevalence, and increased usage of radiotherapy as a primary cancer treatment, which has resulted in increased demand for radiodermatitis products and services.

Recent Development

  • Helsinn closes financing agreement with Oberland Capital - January 2023
  • PERRIGO COMPLETES THE ACQUISITION OF HRA PHARMA - May 2022

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Enterprise Neurotrophic Keratitis, Inc., Hertz Global Holdings, Inc, Michelin Co., Ryder System, Inc, etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Luxemburg, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Qatar, Nigeria, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

  • The report presents a detailed Ansoff matrix analysis for the Global Radiodermatitis Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development, and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.
  • The publisher analyses the Global Radiodermatitis Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • Based on the SWOT analysis conducted on the industry and industry players, the publisher has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Radiodermatitis Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The research report also provides a detailed Market size analysis and projections in volume and value terms. The projections are calculated using verified research methodologies.
  • Excel data sheet for the market size will also be provided with the report.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter’s 5 forces model, PESTLE Analysis, and the Ansoff Matrix. In addition, the impact of COVID-19 on the market is also featured in the report.
  • The report includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report includes Self-Assessment Form, which helps customers evaluate their position in the market compared to their competitors
  • The report offers customized research - tailored uniquely to our customers with a quick turnaround time. We offer a 15% customization option at no extra charge to all our clients for any of our syndicated reports.

Report Highlights:

  • A complete analysis of the market, including the parent industry
  • Important market dynamics and trends
  • Impact Analysis - a comprehensive assessment to confront risk and make strategic & operational decisions to counter the changes in the market environment.
  • Market segmentation
  • Competitive Analysis: Comparative analysis of competitor
  • Historical, current, and projected size of the market based on value and volume
  • Market size of the US states
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research0
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations, and Outlook
4 Market Dynamics
4.1 Impact Analysis
4.2 Drivers
4.2.1 Growth in the Geriatric Population
4.2.2 Increase in Prevalence of Cancer
4.2.3 Rise in the Adoption of Radiotherapy
4.3 Restraints
4.3.1 Higher Radiodermatitis Cost
4.4 Opportunities
4.4.1 Increase in Demand for Reduction of Side Effects associated with Radiation Therapy
4.5 Challenges
4.5.1 Chances of Chronic Skin Changes
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter’s Five Forces Analysis
5.3 PESTLE Analysis
5.4 Impact of COVID-19
5.5 Ansoff Matrix Analysis
6 Global Radiodermatitis Market, By Product
6.1 Introduction
6.2 Topical
6.3 Oral Drugs
6.4 Dressings
7 Global Radiodermatitis Market, By Distribution Channel
7.1 Introduction
7.2 Hospital Pharmacy
7.3 Retail Pharmacy
7.4 Online Pharmacy
8 America’s Radiodermatitis Market
8.1 Introduction
8.2 Argentina
8.3 Brazil
8.4 Canada
8.5 Chile
8.6 Colombia
8.7 Mexico
8.8 Peru
8.9 United States
8.10 Rest of Americas
9 Europe's Radiodermatitis Market
9.1 Introduction
9.2 Austria
9.3 Belgium
9.4 Denmark
9.5 Finland
9.6 France
9.7 Germany
9.8 Ireland
9.9 Italy
9.10 Luxembourg
9.11 Netherlands
9.12 Norway
9.13 Poland
9.14 Russia
9.15 Spain
9.16 Sweden
9.17 Switzerland
9.18 United Kingdom
9.19 Rest of Europe
10 Middle East and Africa's Radiodermatitis Market
10.1 Introduction
10.2 Egypt
10.3 Israel
10.4 Qatar
10.5 Nigeria
10.6 Saudi Arabia
10.7 South Africa
10.8 United Arab Emirates
10.9 Rest of MEA
11 APAC's Radiodermatitis Market
11.1 Introduction
11.2 Australia
11.3 Bangladesh
11.4 China
11.5 India
11.6 Indonesia
11.7 Japan
11.8 Malaysia
11.9 Philippines
11.10 Singapore
11.11 South Korea
11.12 Sri Lanka
11.13 Thailand
11.14 Taiwan
11.15 Rest of Asia-Pacific
12 Competitive Landscape
12.1 Competitive Quadrant
12.2 Market Share Analysis
13 Company Profiles
13.1 Acelity LP Inc.
13.1.1 Company Overview
13.1.2 Company Snapshot
13.1.3 Product Overview
13.1.4 Business Overview
13.1.5 SWOT Analysis
13.1.6 Recent Developments
13.2 AcelRx Pharmaceuticals, Inc.
13.2.1 Company Overview
13.2.2 Company Snapshot
13.2.3 Product Overview
13.2.4 Business Overview
13.2.5 SWOT Analysis
13.2.6 Recent Developments
13.3 Advancis Medical
13.3.1 Company Overview
13.3.2 Company Snapshot
13.3.3 Product Overview
13.3.4 Business Overview
13.3.5 SWOT Analysis
13.3.6 Recent Developments
13.4 Alliqua BioMedical, Inc.
13.4.1 Company Overview
13.4.2 Company Snapshot
13.4.3 Product Overview
13.4.4 Business Overview
13.4.5 SWOT Analysis
13.4.6 Recent Developments
13.5 Bausch Health Companies Inc.
13.5.1 Company Overview
13.5.2 Company Snapshot
13.5.3 Product Overview
13.5.4 Business Overview
13.5.5 SWOT Analysis
13.5.6 Recent Developments
13.6 Bayer Ag
13.6.1 Company Overview
13.6.2 Company Snapshot
13.6.3 Product Overview
13.6.4 Business Overview
13.6.5 SWOT Analysis
13.6.6 Recent Developments
13.7 BMG Pharma S.p.A.
13.7.1 Company Overview
13.7.2 Company Snapshot
13.7.3 Product Overview
13.7.4 Business Overview
13.7.5 SWOT Analysis
13.7.6 Recent Developments
13.8 Convatec Group PLC
13.8.1 Company Overview
13.8.2 Company Snapshot
13.8.3 Product Overview
13.8.4 Business Overview
13.8.5 SWOT Analysis
13.8.6 Recent Developments
13.9 Derma Sciences Inc.
13.9.1 Company Overview
13.9.2 Company Snapshot
13.9.3 Product Overview
13.9.4 Business Overview
13.9.5 SWOT Analysis
13.9.6 Recent Developments
13.10 GlaxoSmithKline PLC
13.10.1 Company Overview
13.10.2 Company Snapshot
13.10.3 Product Overview
13.10.4 Business Overview
13.10.5 SWOT Analysis
13.10.6 Recent Developments
13.11 Helsinn Healthcare SA
13.11.1 Company Overview
13.11.2 Company Snapshot
13.11.3 Product Overview
13.11.4 Business Overview
13.11.5 SWOT Analysis
13.11.6 Recent Developments
13.12 Medline Industries, Inc.
13.12.1 Company Overview
13.12.2 Company Snapshot
13.12.3 Product Overview
13.12.4 Business Overview
13.12.5 SWOT Analysis
13.12.6 Recent Developments
13.13 Molnlycke Health Care AB
13.13.1 Company Overview
13.13.2 Company Snapshot
13.13.3 Product Overview
13.13.4 Business Overview
13.13.5 SWOT Analysis
13.13.6 Recent Developments
13.14 Mylan N.V.
13.14.1 Company Overview
13.14.2 Company Snapshot
13.14.3 Product Overview
13.14.4 Business Overview
13.14.5 SWOT Analysis
13.14.6 Recent Developments
13.15 Perrigo Company plc
13.15.1 Company Overview
13.15.2 Company Snapshot
13.15.3 Product Overview
13.15.4 Business Overview
13.15.5 SWOT Analysis
13.15.6 Recent Developments
13.16 PuriCore Inc.
13.16.1 Company Overview
13.16.2 Company Snapshot
13.16.3 Product Overview
13.16.4 Business Overview
13.16.5 SWOT Analysis
13.16.6 Recent Developments
13.17 RDT Pacific
13.17.1 Company Overview
13.17.2 Company Snapshot
13.17.3 Product Overview
13.17.4 Business Overview
13.17.5 SWOT Analysis
13.17.6 Recent Developments
13.18 Smith & Nephew PLC
13.18.1 Company Overview
13.18.2 Company Snapshot
13.18.3 Product Overview
13.18.4 Business Overview
13.18.5 SWOT Analysis
13.18.6 Recent Developments
13.19 Stratpharma Ag
13.19.1 Company Overview
13.19.2 Company Snapshot
13.19.3 Product Overview
13.19.4 Business Overview
13.19.5 SWOT Analysis
13.19.6 Recent Developments
13.20 The 3M Company
13.20.1 Company Overview
13.20.2 Company Snapshot
13.20.3 Product Overview
13.20.4 Business Overview
13.20.5 SWOT Analysis
13.20.6 Recent Developments
14 Appendix
14.1 Self-Assessment Form

Companies Mentioned

  • Acelity LP Inc.
  • AcelRx Pharmaceuticals, Inc.
  • Advancis Medical
  • Alliqua BioMedical, Inc.
  • Bausch Health Companies Inc.
  • Bayer Ag
  • BMG Pharma S.p.A.
  • Convatec Group PLC
  • Derma Sciences Inc.
  • GlaxoSmithKline PLC
  • Helsinn Healthcare SA
  • Medline Industries, Inc.
  • Molnlycke Health Care AB
  • Mylan N.V.
  • Perrigo Company plc
  • PuriCore Inc.
  • RDT Pacific
  • Smith & Nephew PLC
  • Stratpharma Ag
  • The 3M Company

Table Information